ERBB2 and breast carcinoma: Figure 4 shows how BT474, SKBR3, MDA-MB-453 and MDA-MB-231 breast cancer cells exhibited 0.49, 0.41, 0.24 and 0.01 fold HER2 expression, respectively, when normalized to β-actin.